



## Research on Immune Response and Vaccines

Guest Editor:

**Prof. Dr. James Galloway**

Centre for Rheumatic Disease,  
King's College London, London,  
UK

Deadline for manuscript  
submissions:

**closed (31 January 2024)**

### Message from the Guest Editor

The importance of vaccination has gained much attention, due to the advent of COVID-19 pandemic. The ultimate goal of vaccination is to generate a safe and effective long-term immune response against targeted disease.

Most vaccines work by mimicking infections. Vaccines activate the immune system and generate memory T and B lymphocytes that "remember" the disease-causing agents. Upon encountering these pathogens later, the immune system will mount a rapid and robust immune response to antigens it has previously experienced, thereby preventing disease or reducing its severity. The initial response to a vaccine is similar to the primary response upon first exposure to a pathogen, that is, slow and limited.

In this Special Issue, we will collect articles research related to vaccine efficacy and effectiveness, vaccine failure, herd immunity, herd effect, epidemiological transfer. Specifically, vaccine-related immune responses. We invite research employing quantitative and qualitative methods as well as contributions featuring under-researched populations.





an Open Access Journal by MDPI

## Editor-in-Chief

### **Prof. Dr. Ralph A. Tripp**

Department of Infectious  
Diseases, College of Veterinary  
Medicine, University of Georgia,  
Athens, GA 30602-7387, USA

## Message from the Editor-in-Chief

*Vaccines* (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

## Author Benefits

**Open Access:** free for readers, with **article processing charges (APC)** paid by authors or their institutions.

**High Visibility:** indexed within **Scopus**, **SCIE (Web of Science)**, **PubMed**, **PMC**, **Embase**, **CAPLus / SciFinder**, and **other databases**.

**Journal Rank:** JCR - Q2 (Medicine, Research and Experimental) / CiteScore - Q1 (Pharmacology (medical))

## Contact Us

*Vaccines* Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/vaccines](http://mdpi.com/journal/vaccines)  
[vaccines@mdpi.com](mailto:vaccines@mdpi.com)  
[X@Vaccines\\_MDPI](https://twitter.com/Vaccines_MDPI)